Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
April 06, 2016 17:00 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., April 06, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
March 11, 2016 08:00 ET
|
Progenics Pharmaceuticals Inc.
RELISTOR® Net Sales Increased to $23.0 Million for the Fourth Quarter Oral RELISTOR Remains On-track for April 19, 2016 PDUFASubcutaneous RELISTOR Approved in Europe for All Opioid-Induced...
Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference
March 09, 2016 17:00 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., March 09, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced...
Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2015 Financial Results Call for March 11
March 01, 2016 17:00 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., March 01, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
February 01, 2016 08:45 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced...
Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer
January 07, 2016 08:30 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404,...
Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra™
December 03, 2015 08:30 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has completed enrollment in its Phase 2b clinical trial of its ultra-orphan...
Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer
November 16, 2015 07:30 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced appointment of Patrick Fabbio as Chief Financial Officer. Mr. Fabbio, the...
Progenics Pharmaceuticals to Present at the Stifel Healthcare Conference
November 10, 2015 08:30 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced...
Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results
November 09, 2015 07:30 ET
|
Progenics Pharmaceuticals Inc.
TARRYTOWN, N.Y., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced results of operations for the quarter and nine months ended September 30, 2015. ...